Qiagen expanded its infectious disease diagnostic footprint by receiving CE-IVD certification for its QiaStat-Dx BCID GN Plus AMR Panel, enabling gram-negative pathogen and antimicrobial resistance marker detection in about one hour from positive blood cultures. The faster turnaround is designed to support antibiotic stewardship and infection-control decisions in clinical labs. The panel complements Qiagen’s existing QiaStat-Dx BCID GPF Plus AMR Panel for gram-positive and fungal targets, both running on the same PCR-based system. Together, the panels aim to provide one-hour actionable coverage across key bloodstream-infection targets. Separately, Juno Bio raised $3.8 million and opened a CLIA-certified sequencing lab in Oakland to scale its vaginal microbiome assay, including support for pharmaceutical R&D partnerships and testing availability across the U.S.